Lupus Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus
Verified date | January 2014 |
Source | Amgen |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This study will be a multicenter, randomized, double-blind, placebo-controlled, multiple dose study in which approximately 24 subjects with SCLE will be enrolled. Cohort 1 will consist of 12 subjects (6 AMG 557: 6 placebo) randomized to receive AMG 557 210 mg or matching placebo. Cohort 2 will consist of 12 subjects (6 AMG 557: 6 placebo) randomized to receive AMG 557 140 mg or matching placebo. Enrollment of Cohort 2 (140 mg) will be initiated after enrollment of Cohort 1 (210 mg) is completed.
Status | Terminated |
Enrollment | 1 |
Est. completion date | March 2013 |
Est. primary completion date | March 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Men and women, between the ages of 18 and 70 years of age, inclusive, at the time of randomization; - Body mass index from 18 to 35 kg/m2 at screening; - Diagnosis of subacute cutaneous lupus erythematosus (SCLE) with or without systemic lupus erythematosus (SLE). SCLE as defined by the Gilliam and Sontheimer classification (J Am Acad Dermatol 1981; 4(4):471-475). SLE is defined by the most recent American College of Rheumatology criteria, including positive antinuclear antibodies (ANA) during screening or by documented history (at least 1:80 by indirect immunofluorescent assay); - A history of skin biopsy consistent with the diagnosis of SCLE; - Positive SS-A and/or SS-B antibodies at screening; - Intolerance of anti-malarial therapy or = 3 months of anti-malarial therapy with residual disease activity as defined by: at least 2 areas with at least level 2 erythema or 3 areas with at least level 1 erythema using cutaneous lupus erythematosus disease area and severity index (CLASI). The total CLASI activity must be = 10; - Subject must have stable disease activity for 3 months prior to screening in the clinical judgment of the Principal Investigator (PI) with no anticipated changes in therapy; - Stable dose of topical steroids no stronger than medium-potency (Class III or Class VII) for = 2 weeks from screening is permitted; - Prednisone = 10 mg/day (or equivalent) is permitted; - Stable doses of methotrexate = 20 mg/week, azathioprine = 150 mg/day, and 6-mercaptopurine = 150 mg/day for 12 weeks prior to screening are permitted. - Exclusion Criteria: - Drug-induced SCLE; - Any disorder (including psychiatric), condition or clinically significant disease (other than a diagnosis of SCLE, SLE, or Sjögren's syndrome) that would, by its progressive nature and/or severity, interfere with the study evaluation, completion and/or procedures per the investigator's discretion. This includes any age related co-morbidities such as presence of congestive heart failure, angina, chronic obstructive pulmonary disease, and asthma; - Presence or history of vasculitis (comprising internal organs or extremities or leading to peripheral neuropathy) within the last 3 years, presence or history of active Central Nervous System (CNS) lupus (defined as seizure disorder, cerebral vascular accident, psychosis ascribed to SLE , encephalitis, meningitis, and myelitis) requiring therapy within the last 3 years; - History of malignancy; - Signs or symptoms of a viral, bacterial or fungal infection within 30 days of study randomization, or recent history of repeated infections; - Underlying condition other than SCLE, SLE, Sjögren's syndrome that predisposes one to infections (eg, history of splenectomy); - Administration of >10 mg/day prednisone (or equivalent) in the 30 days prior to randomization; - Prior use of any following biological agents: Rituximab, Lymphostat-B, TACl-Ig, and CTLA4-Ig; - Current treatment (within 3 months or 5 half-lives of screening) with thalidomide, mycophenolate mofetil, cyclosporine, tacrolimus, sirolimus, Intravenous (IV) immunoglobulin, plasmapheresis, oral or IV cyclophosphamide; - Receiving or has received any investigational drug (or is currently using an investigational device) within the 30 days or 5 half-lives (whichever is longer), prior to receiving the first dose of study medication). - 29. Use of any other over-the-counter or prescription medications within the 14 days or 5 half-lives (whichever is longer), prior to receiving the first dose of study medication. Acetaminophen (up to 2 g per day) for analgesia and hormone replacement therapy (eg, estrogen, thyroid) will be allowed. In addition, prescription drugs for hypertension or hypercholesterolemia, oral hypoglycemic drugs, or NSAIDs will be allowed; however, NSAIDS are not permitted within 24 hours of skin biopsies to reduce the risk of bleeding. Other medications may be approved following review by the Principal Investigator and the Amgen Medical Monitor. Written documentation of this review and Amgen acknowledgement is required for subject participation; |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Research Site | Carlton | Victoria |
Australia | Research Site | Woolloongabba | Queensland |
Canada | Research Site | Peterborough | Ontario |
United States | Research Site | Ann Arbor | Michigan |
United States | Research Site | Austin | Texas |
United States | Research Site | Birmingham | Alabama |
United States | Research Site | Dallas | Texas |
United States | Research Site | Dallas | Texas |
United States | Research Site | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Amgen |
United States, Australia, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety evaluation: Subject incidence of treatment-emergent adverse events, vital signs, physical examinations, clinical laboratory safety tests, ECGs, and the incidence of binding and neutralizing antibodies to AMG 557 | 253 Days | Yes | |
Secondary | Determine the pharmacokinetic (PK) profile of AMG 557 after multiple subcutaneous (SC) doses in subacute cutaneous lupus erythematosus (SCLE) subjects. | 253 Days | No | |
Secondary | Characterize the mean change and variability in serum SS-A and SS-B autoantibodies. | 253 Days | No | |
Secondary | Characterize change in Cutaneous Lupus Erythematosus Disease Area and Severity Index score (CLASI-a) score. | 253 Days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06013995 -
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
|
Phase 1 | |
Recruiting |
NCT03952624 -
Patient-Centered Assessment of Symptoms and Outcomes
|
||
Completed |
NCT00710021 -
Vitamin D3 in Systemic Lupus Erythematosus
|
Phase 2 | |
Completed |
NCT02265744 -
Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus
|
Phase 2 | |
Recruiting |
NCT06445127 -
Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)
|
N/A | |
Completed |
NCT00581763 -
Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies
|
N/A | |
Recruiting |
NCT01172002 -
Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
|
N/A | |
Completed |
NCT00299819 -
Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
Completed |
NCT00054938 -
Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)
|
Phase 2 | |
Terminated |
NCT03953690 -
Acceptability and Persistence of the Use of a Patient-centred E-health Tool for Lupus Patients Followed in a Specialised Centre in France
|
||
Recruiting |
NCT05715463 -
Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity
|
N/A | |
Enrolling by invitation |
NCT05321108 -
Aerobic Exercise Versus Whole-Body Vibration on Fatigue, Functional Capacity, Quality of Life in Systemic Lupus
|
N/A | |
Completed |
NCT00482989 -
A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus
|
Phase 1 | |
Completed |
NCT00657189 -
A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus
|
Phase 2 | |
Recruiting |
NCT04334031 -
Deployment o the Multidisciplinary Prospective Cohort Imminent
|
N/A | |
Completed |
NCT03402087 -
A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients
|
Phase 1 | |
Completed |
NCT02857452 -
Transcultural Validation in French of the Systemic Lupus Activity Questionnaire (SLAQ) and the Lupus Quality Of Life (LupusQoL) Questionnaire
|
N/A | |
Terminated |
NCT03186794 -
Aerobic Exercise in Women With Systemic Lupus Erythematosus
|
N/A | |
Recruiting |
NCT05922722 -
Clarifying Misbeliefs About Hydroxychloroquine: Developing a Decision Aid for Patients With Lupus
|
||
Completed |
NCT03093402 -
JBT-101 in Systemic Lupus Erythematosus (SLE)
|
Phase 2 |